Literature DB >> 10193767

Effects of varying the expression level of recombinant human mGlu1alpha receptors on the pharmacological properties of agonists and antagonists.

E Hermans1, R A Challiss, S R Nahorski.   

Abstract

1. Different expression levels of the human type 1alpha metabotropic glutamate (mGlu1alpha) receptor were obtained in transfected Chinese hamster ovary cells using an isopropyl beta-D-thiogalactopyranoside (IPTG) inducible system. Expression of mGlu1alpha receptors could not be detected using immunoblotting or immunocytochemical approaches in non-induced cells, however, controlled expression could be induced following IPTG addition in a time- and concentration-dependent manner. 2. In induced cells (100 microM IPTG, 20 h) the agonists L-quisqualate or 1-aminocyclopentane-1S,3R-dicarboxylic acid stimulated large increases in [3H]-inositol (poly)phosphate (in the presence of Li+) and inositol, 1,4,5-trisphosphate levels. 3. Induction with 1-100 microM IPTG allowed the receptor density to be increased incrementally and this not only resulted in an increase in the maximum response to L-quisqualate, 1-aminocyclopentane-1S,3R-dicarboxylic acid and (S)-3,5-dihydroxy-phenylglycine, but also in an increase in the respective potencies of each agent to activate phosphoinositide hydrolysis. 4. The intrinsic activity of the partial agonist 1-aminocyclopentane-1S,3R-dicarboxylic acid dramatically increased with increasing receptor expression. 5. The activities of the competitive mGlu1alpha receptor antagonists (S)-alpha-methyl-4-carboxyphenylglycine and (S)-4-carboxy-3-hydroxyphenylglycine for inhibition of the effects of L-quisqualate or (S)-3,5-dihydroxyphenylglycine were found to be independent of the receptor expression level. 6. When the mGlu1alpha receptor was expressed at very high levels, no evidence for receptor constitutive activity could be detected, and none of the antagonists tested revealed either any intrinsic activity or negative efficacy. 7. These data demonstrate that both the potency and efficacy of mGlu1alpha receptor agonists are influenced by expression level, whilst mGlu1alpha receptor antagonist activities are independent of expression level.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10193767      PMCID: PMC1571208          DOI: 10.1038/sj.bjp.0702359

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  28 in total

1.  Metabotropic glutamate receptor mGluR5 in astrocytes: pharmacological properties and agonist regulation.

Authors:  R Balázs; S Miller; C Romano; A de Vries; Y Chun; C W Cotman
Journal:  J Neurochem       Date:  1997-07       Impact factor: 5.372

2.  (RS)-2-chloro-5-hydroxyphenylglycine (CHPG) activates mGlu5, but no mGlu1, receptors expressed in CHO cells and potentiates NMDA responses in the hippocampus.

Authors:  A J Doherty; M J Palmer; J M Henley; G L Collingridge; D E Jane
Journal:  Neuropharmacology       Date:  1997-02       Impact factor: 5.250

Review 3.  Pharmacology and functions of metabotropic glutamate receptors.

Authors:  P J Conn; J P Pin
Journal:  Annu Rev Pharmacol Toxicol       Date:  1997       Impact factor: 13.820

Review 4.  Neuronal Ca2+ stores: activation and function.

Authors:  P B Simpson; R A Challiss; S R Nahorski
Journal:  Trends Neurosci       Date:  1995-07       Impact factor: 13.837

5.  Pharmacological characterization of 1-aminoindan-1,5-dicarboxylic acid, a potent mGluR1 antagonist.

Authors:  F Moroni; G Lombardi; C Thomsen; P Leonardi; S Attucci; F Peruginelli; S A Torregrossa; D E Pellegrini-Giampietro; R Luneia; R Pellicciari
Journal:  J Pharmacol Exp Ther       Date:  1997-05       Impact factor: 4.030

6.  Pharmacological characterization of type 1alpha metabotropic glutamate receptor-stimulated [35S]-GTPgammaS binding.

Authors:  E C Akam; A M Carruthers; S R Nahorski; R A Challiss
Journal:  Br J Pharmacol       Date:  1997-07       Impact factor: 8.739

7.  Inducible expression of beta 1- and beta 2-adrenergic receptors in rat C6 glioma cells: functional interactions between closely related subtypes.

Authors:  H Zhong; S W Guerrero; T A Esbenshade; K P Minneman
Journal:  Mol Pharmacol       Date:  1996-07       Impact factor: 4.436

8.  Cloning and expression of a human metabotropic glutamate receptor 1 alpha: enhanced coupling on co-transfection with a glutamate transporter.

Authors:  M A Desai; J P Burnett; N G Mayne; D D Schoepp
Journal:  Mol Pharmacol       Date:  1995-10       Impact factor: 4.436

9.  Changes in the carboxyl-terminal domain of metabotropic glutamate receptor 1 by alternative splicing generate receptors with differing agonist-independent activity.

Authors:  L Prézeau; J Gomeza; S Ahern; S Mary; T Galvez; J Bockaert; J P Pin
Journal:  Mol Pharmacol       Date:  1996-03       Impact factor: 4.436

10.  Differences in agonist and antagonist activities for two indices of metabotropic glutamate receptor-stimulated phosphoinositide turnover.

Authors:  R Mistry; R A Challiss
Journal:  Br J Pharmacol       Date:  1996-04       Impact factor: 8.739

View more
  11 in total

1.  Pharmacological blockade of dopamine D2 receptors by aripiprazole is not associated with striatal sensitization.

Authors:  Beryl Koener; Stéphanie Goursaud; Morgane Van De Stadt; André-Guilhem Calas; Anne P Jeanjean; Jean-Marie Maloteaux; Emmanuel Hermans
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2011-01       Impact factor: 3.000

2.  Somatostatin receptor-mediated arachidonic acid mobilization: evidence for partial agonism of synthetic peptides.

Authors:  F Alderton; T P Fan; P P Humphrey
Journal:  Br J Pharmacol       Date:  2001-02       Impact factor: 8.739

3.  Group I mGluR-regulated translation of the neuronal glutamate transporter, excitatory amino acid carrier 1.

Authors:  John R Ross; Hariharasubramanian Ramakrishnan; Brenda E Porter; Michael B Robinson
Journal:  J Neurochem       Date:  2011-04-11       Impact factor: 5.372

4.  The P2Y(1) receptor closes the N-type Ca(2+) channel in neurones, with both adenosine triphosphates and diphosphates as potent agonists.

Authors:  A K Filippov; D A Brown; E A Barnard
Journal:  Br J Pharmacol       Date:  2000-03       Impact factor: 8.739

5.  The melanocortin-4 receptor: physiology, pharmacology, and pathophysiology.

Authors:  Ya-Xiong Tao
Journal:  Endocr Rev       Date:  2010-02-26       Impact factor: 19.871

Review 6.  Structural, signalling and regulatory properties of the group I metabotropic glutamate receptors: prototypic family C G-protein-coupled receptors.

Authors:  E Hermans; R A Challiss
Journal:  Biochem J       Date:  2001-11-01       Impact factor: 3.857

7.  Single-cell imaging of graded Ins(1,4,5)P3 production following G-protein-coupled-receptor activation.

Authors:  M S Nash; K W Young; G B Willars; R A Challiss; S R Nahorski
Journal:  Biochem J       Date:  2001-05-15       Impact factor: 3.857

8.  Receptor density as a factor governing the efficacy of the dopamine D4 receptor ligands, L-745,870 and U-101958 at human recombinant D4.4 receptors expressed in CHO cells.

Authors:  L Gazi; I Bobirnac; M Danzeisen; E Schüpbach; D Langenegger; B Sommer; D Hoyer; M Tricklebank; P Schoeffter
Journal:  Br J Pharmacol       Date:  1999-10       Impact factor: 8.739

Review 9.  Glutamate, glutamate receptors, and downstream signaling pathways.

Authors:  Stacey S Willard; Shahriar Koochekpour
Journal:  Int J Biol Sci       Date:  2013-09-22       Impact factor: 6.580

10.  Differential ability of the dorsal and ventral rat hippocampus to exhibit group I metabotropic glutamate receptor-dependent synaptic and intrinsic plasticity.

Authors:  Patrick Tidball; Hannah V Burn; Kai Lun Teh; Arturas Volianskis; Graham L Collingridge; Stephen M Fitzjohn
Journal:  Brain Neurosci Adv       Date:  2017-01-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.